Ozmosi | Camostat Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

Camostat

Alternative Names: camostat, foy-305, foy305, foy 305, qau-145, qau145, qau 145
Clinical Status: Inactive
Latest Update: 2025-04-18
Latest Update Note: Clinical Trial Update

Product Description

Camostat is an orally bioavailable, synthetic serine protease inhibitor, with anti-inflammatory, antifibrotic, and potential antiviral activities. Upon oral administration, camostat and its metabolite 4-(4-guanidinobenzoyloxyl)phenyl acetic acid (FOY 251) inhibit the activities of a variety of proteases, including trypsin, kallikrein, thrombin and plasmin, and C1r- and C1 esterases.  (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Camostat)

Mechanisms of Action: SP Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: *

Approval Status: Not Approved

Approved Countries: India | Korea | Philippines

Approved Indications: None

Known Adverse Events: None

Company: KU LEUVEN
Company Location:
Company Founding Year: None
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 4: COVID-19

Phase 3: Severe Acute Respiratory Syndrome|COVID-19|Communicable Diseases

Phase 2: Hypertension|Obesity|COVID-19|Cystic Fibrosis|Severe Acute Respiratory Syndrome|Respiratory Tract Infections|Communicable Diseases|Kidney Diseases|Proteinuria

Phase 1: Healthy Volunteers|COVID-19|Communicable Diseases|Severe Acute Respiratory Syndrome

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT04652765

COMBO

P1

Terminated

COVID-19|Severe Acute Respiratory Syndrome|Communicable Diseases

2021-09-15

2023-10-07

Primary Endpoints|Treatments

JapicCTI-205326

JapicCTI-205326

P1

Unknown

COVID-19

2020-08-31

NCT04451083

FOY-305-02

P1

Completed

Healthy Volunteers

2020-08-17

88%

2021-06-17

Primary Endpoints

2023-508516-34-00

2023-508516-34-00

P2

Recruiting

Kidney Diseases|Proteinuria

2025-12-31

2025-05-02

Treatments

NCT04625114

COV-AAT

P2

Terminated

COVID-19

2022-07-12

2024-08-10

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT04662086

COPPS-Master Protocol

P2

Completed

COVID-19

2022-05-03

2023-03-30

Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT04470544

RECOVER

P2

Completed

Severe Acute Respiratory Syndrome

2021-12-22

2024-11-13

NCT04321096

CamoCO-19

P2

Completed

COVID-19|Communicable Diseases

2022-01-31

2025-04-19

Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT04681430

RES-Q-HR

P2

Completed

Communicable Diseases|COVID-19|Respiratory Tract Infections

2021-10-29

2022-02-12

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

NCT04750759

NICCAM

P2

Terminated

COVID-19

2021-10-29

30%

2021-12-10

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

2020-001200-42

2020-001200-42

P2

Terminated

COVID-19

2021-09-06

2022-03-13

Treatments

2020-003475-18

COV-AAT

P2

Completed

Severe Acute Respiratory Syndrome|COVID-19

2021-06-24

NCT04530617

NCT04530617

P2

Terminated

COVID-19|Obesity|Hypertension

2021-06-10

2021-06-22

Primary Endpoints

NCT04662073

COPPS

P2

Terminated

COVID-19

2021-06-08

2022-12-14

Primary Completion Date|Primary Endpoints|Study Completion Date

2020-002233-15

2020-002233-15

P2

Completed

COVID-19

2021-05-26

2022-03-13

Treatments

NCT04524663

COPS-2003

P2

Completed

COVID-19

2021-05-15

2022-06-11

Patient Enrollment|Primary Endpoints

NCT04374019

MCC-20-COVID-01-PMC

P2

Terminated

COVID-19

2020-12-21

2022-01-21

NCT00506792

CQAU145A2201

P2

Completed

Cystic Fibrosis

2008-12-01

2019-03-21

NCT04730206

DAWN

P3

Terminated

Severe Acute Respiratory Syndrome|COVID-19

2022-07-13

2022-10-06

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

2020-002110-41

SPIKE-1

P3

Unknown status

COVID-19

2022-06-18

2022-03-13

Treatments

NCT04657497

FOY-305-01

P3

Completed

COVID-19|Communicable Diseases

2021-03-26

16%

2021-06-15

Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status

2020-003366-39

2020-003366-39

P3

Active, not recruiting

COVID-19

None

2022-03-13

Treatments

NCT04338906

CLOCC

P4

Withdrawn

COVID-19

2021-12-01

2023-02-18

Primary Endpoints|Treatments